giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, her2-negative...
Published 2 years ago • 718 plays • Length 4:45Download video MP4
Download video MP3
Similar videos
-
2:02
palbociclib combined with fulvestrant in relapsed metastatic hr /her2- breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
7:09
palbociclib endocrine therapy vs capecitabine for hr-positive her2-negative breast cancer: pearl
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
9:54
palbociclib endocrine therapy for hormone-positive her2-negative metastatic breast cancer: 5 cases
-
14:31
p-reality-x: real-world, overall survival with palbociclib aromatase inhibitor in hr /her2- mbc
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
2:43
about advanced breast cancer treatment ibrance (palbociclib)
-
0:40
comprehensive guide to palbociclib 125 mg: usage, benefits, and side effects
-
0:40
anastrozole reduces breast cancer risk in post-menopausal women
-
1:49
palbociclib combo therapies for advanced breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
3:07
young-pearl: palbociclib plus exemestane and ofs in hr /her2- breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer